, 1:99 | Cite as

The antirheumatic gold complexes: Considerations of chemical form in studies on their mechanism of action

  • G. G. Graham
  • G. D. Champion
  • J. B. Ziegler


  1. 1.
    Champion GD, Graham GG, Ziegler JB. The gold complexes Bailliere's Clin Rheumatol. 1990;4(3):491–534.CrossRefGoogle Scholar
  2. 2.
    Grootveld MC, Razi MT, Sadler PJ. Progress in the characterization of gold drugs. Clin Rheumatol. 1984;3(Suppl 1):5–16.PubMedGoogle Scholar
  3. 3.
    Jellum E, Munthe E, Guldal G, Aaseth J. Gold and thiol compounds in the treatment of rheumatoid arthritis: excretory fate and tissue distribution of thiomalate in relation to gold after administration of Myocrisin (auro-thiomalate). Scand J Rheumatol. 1979;Suppl 28:28–36.Google Scholar
  4. 4.
    Danpure C, Fyfe DA, Gumpel JM: Distribution of gold among plasma fractions in rheumatoid patients undergoing chrysotherapy compared with its distribution in plasma incubated with aurothiomalate in vitro. Ann Rheum Dis. 1979;38:364–370.PubMedGoogle Scholar
  5. 5.
    Shaw CF, Isab AA, Coffer MT, Mirabelli CK. Gold(I) efflux from auranofin-treated red blood cells. Evidence for a glutathione-gold-albumin metabolite. Biochem Pharmacol. 1990;40:1227–1234.PubMedCrossRefGoogle Scholar
  6. 6.
    Shaw CF, Schaeffer NA, Elder RC, Eidsness MK, Trooster JM, Calis GH. Bovine serum albumin-gold complex:197Au Mossbauer, EXAFS and XANES, electrophoresis,35S-radiotracer, and fluorescent probe competition studies. J Am Chem Soc. 1984;106:3511–3521.CrossRefGoogle Scholar
  7. 7.
    Heath MJ, Gillett GT, Swannell AJ, Williams CR, Palmer, T. Patterns of gold levels in urine, serum and saliva in patients with rheumatoid arthritis undergoing chrysotherapy. Ann Rheum Dis. 1987;46:827–829.PubMedGoogle Scholar
  8. 8.
    Taylor A, King LJ, Marks V. Tissue disposition and excretion of gold and14C in rats treated with sodium aurothiol[1,4-14C]malate or thio[1,4-14C]malic acid. Xenobiotica. 1985;15:221–226.PubMedCrossRefGoogle Scholar
  9. 9.
    Kean WF, Lock CJL, Kassam YB, Rooney PJ, Rischke J, Nablo L, Buchanan WW. A biological effect on platelets by the minor component of gold sodium thiomalate—a by-product of heat sterilization and exposure to light. Clin Exp Rheumatol. 1984;2:321–328.PubMedGoogle Scholar
  10. 10.
    Rudkowski R, Graham GG, Ziegler JB, Champion GD. The effect of aurothiomalate on the oxidative burst of polymorphonuclear leukocytes varies with the quantity of drug in Myocrisin ampoules. J Rheumatol. 1991;18:666–671.PubMedGoogle Scholar
  11. 11.
    The Merck Manual, 14th Ed. Merck Rahway;1982:p 1181.Google Scholar
  12. 12.
    Stelmaszynska T. Formation of HCN and its chlorination to ClCN by stimulated human neutrophils-2. Oxidation of thiocyanate as a source of HCN. Int J Biochem. 1986;18:1107–1114.PubMedCrossRefGoogle Scholar
  13. 13.
    Rudkowski R, Graham GG, Champion GD Ziegler JB. The activation of gold complexes produced by polymorphonuclear leukocytes. 1. The effects of aurocyanide on the oxidative burst of polymorphonuclear leukocytes. Biochem Pharmacol. 1990;39:1687–1695.PubMedCrossRefGoogle Scholar
  14. 14.
    Graham GG, Dale MM. The activation of gold complexes by cyanide produced by polymorphonuclear leukocytes. 2. Evidence for the formation and activity of aurocyanide. Biochem Pharmacol. 1990;39:1697–1702.PubMedCrossRefGoogle Scholar
  15. 15.
    Oxborrow SM, Champion GD, Graham GG, Rudkowski R, Ziegler JB. The activation of protein bound gold by polymorphonuclear leukocytes. Clin Exp Pharmacol Physiol. 1990;Suppl, 16:207.Google Scholar
  16. 16.
    Walz DT, DiMartino MJ, Griswold DE. Differences in the mechanism of action between oral and parenteral gold. Rheumatology. 1983;8:99–117Google Scholar
  17. 17.
    Beverly B, Couri D. Role of myeloperoxidase (MPO) in aurothiomalate metabolism. Fed Proc. 1987;46:854.Google Scholar
  18. 18.
    Grootveld M, Blake DR, Sahinoglu T, Claxson AWD, Mapp P, Stevens, C, Allen RE, Furst A. Control of oxidative damage in rheumatoid arthritis by gold(I)-thiolate drugs. Free, Radical Res. Comm. 1990;10:199–200.CrossRefGoogle Scholar
  19. 19.
    Shuhmann D, Kubicka-Muranyi M, Mirtschewa J, Gunther J, Kind P, Gleichmann E. Adverse immune reactions to gold. 1. Chronic treatment with an Au(I) drug sensitizes mouse T cells not to Au(I), but to-Au(III) and, induces autoantibody formation. J Immunol. 1990;145:2132–2139.Google Scholar
  20. 20.
    Sadler PJ. Gold, silver, ligands and cytotoxicity. Second international conference on gold and silver in medicine. 1990.Google Scholar
  21. 21.
    Schmitz G, Minkel DT, Gingrich D, Shaw CF. The binding of gold(I) to metallothionein. J Inorg Biochem. 1980;12:293–306.PubMedCrossRefGoogle Scholar
  22. 22.
    Shaw CF, Schmitz G, Thompson HO, Witkiewicz P. Bis(l-cysteinato)gold(I): chemical characterization and identification in renal cortical cytoplasm. J Inorg Biochem. 1979;10:317–330.PubMedCrossRefGoogle Scholar
  23. 23.
    Ghadially FN. Ultrastructural localisation andin situ analysis of iron, bismuth and gold inclusions. CRC Crit Rev Toxicol. 1979;6:303–350.PubMedGoogle Scholar
  24. 24.
    Snyder RM, Mirabelli CK, Crooke ST. Cellular association, intracellular distribution, and efflux of auranofin via sequential ligand exchange reactions. Biochem Pharmacol. 1986;35:923–932.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers bv 1991

Authors and Affiliations

  • G. G. Graham
    • 1
    • 2
  • G. D. Champion
    • 1
    • 2
  • J. B. Ziegler
    • 1
    • 2
  1. 1.School of Physiology and PharmacologyUniversity of NSWRandwickAustralia
  2. 2.Prince of Wales Childern's HospitalRandwickAustralia

Personalised recommendations